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In 1887, Merck 
opened its own office 
in New York, which 
gave rise to the 
subsidiary Merck & 
Co. three years later. 
As a result of World 
War I, this subsidiary 
was expropriated in 
1917 and has been an 
independent company 
ever since 1917. 
Merck –
the original
holds the global
rights  to the Merck 
name and brand. 
Exceptions are 
Canada and the 
United States,
where we do busi-
ness as EMD Serono,
EMD Millipore and 
EMD Performance 
Materials. 
WE ARE MERCK –
THE ORIGINAL
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3 business areas
What we do
Life Science
Performance
Materials
Healthcare
A wide range of specialty chemicals, 
such as liquid crystals for displays, 
effect pigments for coatings and 
cosmetics, or high-tech materials 
for the electronics industry. 
Innovative tools and laboratory
supplies for the life science industry 
that make research and biotech
production easier, faster and more 
successful. 
Prescription medicines to treat, for 
example, cancer, multiple sclerosis 
and infertility, over-the-counter 
pharmaceuticals for everyday health 
protection or to provide fast relief of 
colds and pain, as well as innovations 
in the areas of allergies and 
biosimilars.
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Product portfolio
EMD Serono has experience in perfusion and fed-batch
During the 90s
Perfusion processes for low productive processes and labile 
molecules (using different types of carriers)                  
Past decade
Fed-batch processes for stable proteins and high productive 
processes (mAbs) 
Infertility Neurology
Oncology Growth & 
metabolism
5Platform available including proprietary chemically defined media
Lab scale process development Manufacturing
Throughput
Volume
96-deepwell 
plates
Shake 
tubes
Micro-scale
bioreactors
Lab-scale 
bioreactors
Orbital shaking Stirred tank bioreactors
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Fed-batch process
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Perfusion process
We are not going back to our perfusion processes of the 90s
µ-carriers 
Fixed-bed Alternating tangential flow filtration
Attached cells Cells in suspension
Perfusion process development supported by our expertise 
in cell culture and media development
7Limited scale and throughput range for perfusion development
Lab scale process development Manufacturing
Throughput
Volume
96-deepwell 
plates
Shake 
tubes
Micro-scale
bioreactors
Lab-scale 
bioreactors
Orbital shaking Stirred tank bioreactors
OK?
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Perfusion process development tools
FIRST STEPS IN 
PERFUSION PROCESS
DEVELOPMENT
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First steps
erEvaluate perfusion technology
STRATEGY
• Platform media
• Maintain steady-state
• Media enrichment (↑ VCD, ↓ CSPR)
• Temperature
• O2 (↑ kLa, ↓ foam, scale-up)
• Test different cell lines
TARGET
• 1 g/Lbio/day protein
• 1 wvd-1
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Learning the hard way
Lab set-up for 2 bioreactors
• ATF
• Continuous bleed
• Capacitance probe to monitor biomass
• Scale control based on calibration
• Lack of flowrate control…
A FEW CASE STUDIES
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Case studies
1. Easy-switch
2. Increasing perfusion rate
3. Temperature switch
4. Using perfusion rate and temperature
5. Thoughts about VCD control
6. Media enrichment
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1. Easy switch
Fed-batch platform media for perfusion
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Perfusion rate used = 1 wvd-1
Fixed bleed based on preliminary observations
Growth phase
Steady-state, media supports about 20 
millions cells per mL at 1 wvd-1
Change conditions to see effect on steady-
state to test different conditions in a single 
run
Bleed stopped and use of enriched media
Temperature switch
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2. Increasing perfusion rate
No lactate or ammonium accumulation
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Time [day]
↑ perfusion rate = ↑ VCD
Bleed rate adapted for each condition (20 → 60 → T shift)
T shift at day 25 → bleed stopped
No amino acid depletion measured
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3. Temperature switch
Reduce perfusion rate and increase productivity
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↓ Perfusion rate (CSPR from about 50 to 25 pL/cell/day)
↑ Specific productivity
0
20
40
60
80
100
0 5 10 15 20 25
VCD
Viability
0
1
2
3
4
5
6
0
10
20
30
40
0 5 10 15 20 25
Temperature
Perfusion rate
V
C
D
 [
1
0
6
V
C
/m
L
]
S
p
e
c
if
ic
p
ro
d
u
c
ti
v
it
y
[p
g
/c
e
ll
/d
a
y
]
Time [day]
0
2
4
6
8
10
0
20
40
60
80
10 15 20 25
VCD
Specific productivity
16 Upstream Perfusion Process| 02.11.2015
4. Using perfusion rate and temperature
Switch from growth phase to steady-state is sensitive
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VCD drop when growth phase is stopped (recurrent issue)
No glucose or amino acid depletion observed
Cell metabolism changes 
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5. Thoughts about VCD control
Self maintaining steady-state or feedback loop?
bleeddeathgrowth µµµ 
1. Can we reach steady-state without a feedback loop on VCD?
No feedback control loop
Fixed bleed and perfusion rate
2. Do we need a signal to monitor and control the bleed online?
Feedback control loop for biomass
Bleed varies depending on signal
http://cercell.com/media/1460/fogale-capacitance-how-does-it-work.pdf
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6. Media enrichment
Concentrate media without affecting compound balance
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Amino acids
Vitamines
Trace elements
etc
Glucose
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6. Media enrichment
Batch evaluation of NaCl depleted formulation at different concentrations
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CONCLUSION
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Conclusion
• Perfusion with the platform media and 20 million cells per mL at 1 wvd-1
• Increased perfusion rate to explore steady-states at about 60 million cells per mL
• Observed effect of temperature change
• Media concentration strategy tests in batch mode encouraging
Next Steps
• Volume control implementation
• VCD control strategy needs to be defined
• Increase perfusion capacity in our development lab
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